Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jane Griffiths

- PMLiVE

Novel anticoagulant antidotes prove their worth

Reversal agents from Portola and BMS and Boehringer shine in late-stage clinical trials

- PMLiVE

Astellas’ Xtandi cancer drug rejected by NICE

England’s HTA questions the treatment’s efficacy and cost

- PMLiVE

Just manufacturing pills ‘no longer good enough for patients’

Pharma must truly move beyond the pill and embrace digital health, according to industry heads

Gilead Sciences

Humira remains top pharma product, but Sovaldi closes in

AbbVie’s blockbuster may be bumped to second place this year

Boehringer Ingelheim headquarters

NICE U-Turn on Boehringer oncology drug

England’s drug price watchdog now recommends Vargatef for lung cancer after price cut

- PMLiVE

Boehringer launches iPhone app for patients on Gilotrif

App offers treatment guide for those taking its cancer drug

- PMLiVE

Novartis and Google to fund ‘robotic pill’ maker

Firms sign up to Rani Therapeutics’ new drug delivery system

Boehringer Ingelheim headquarters

Boehringer bags FDA approval for Spiriva-based combo

Stiolto given the thumbs up as a once-daily maintenance therapy for COPD

- PMLiVE

FDA approves J&J’s schizophrenia drug Invega Trinza

New version of Invega is the first treatment for the condition to require only four doses a year

- PMLiVE

Boehringer signs digital health collaboration with Sutter Health

Workwill start in COPD with a personalised medical care project

- PMLiVE

Sobi launches disease awareness app with UK hospital

Pharma firm links with GOSH on helping children with haemophilia

- PMLiVE

J&J takes external advice on compassionate use

Drugmaker will run a pilot for a review of one late-stage project

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links